174 related articles for article (PubMed ID: 32909245)
1. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts.
Tran A; Koh TS; Prawira A; Ho RZW; Le TBU; Vu TC; Hartano S; Teo XQ; Chen WC; Lee P; Thng CH; Huynh H
Mol Imaging Biol; 2021 Feb; 23(1):70-83. PubMed ID: 32909245
[TBL] [Abstract][Full Text] [Related]
2. Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma.
Huynh H; Lee LY; Goh KY; Ong R; Hao HX; Huang A; Wang Y; Graus Porta D; Chow P; Chung A
Hepatology; 2019 Mar; 69(3):943-958. PubMed ID: 30575985
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma.
Le TBU; Vu TC; Ho RZW; Prawira A; Wang L; Goh BC; Huynh H
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321903
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor.
Prawira A; Le TBU; Ho RZW; Huynh H
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2955-2968. PubMed ID: 34156519
[TBL] [Abstract][Full Text] [Related]
5. Ribociclib enhances infigratinib-induced cancer cell differentiation and delays resistance in FGFR-driven hepatocellular carcinoma.
Prawira A; Le TBU; Vu TC; Huynh H
Liver Int; 2021 Mar; 41(3):608-620. PubMed ID: 33179425
[TBL] [Abstract][Full Text] [Related]
6. Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma.
Tai DWM; Le TBU; Prawira A; Ho RZW; Huynh H
Hepatol Int; 2021 Oct; 15(5):1236-1246. PubMed ID: 34333737
[TBL] [Abstract][Full Text] [Related]
7. Comparison of dynamic contrast-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for evaluation of the effects of sorafenib in a rat model of hepatocellular carcinoma.
Muñoz NM; Minhaj AA; Maldonado KL; Kingsley CV; Cortes AC; Taghavi H; Polak U; Mitchell JM; Ensor JE; Bankson JA; Rashid A; Avritscher R
Magn Reson Imaging; 2019 Apr; 57():156-164. PubMed ID: 30465870
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of tumor microvascular response to brivanib by dynamic contrast-enhanced 7-T MRI in an orthotopic xenograft model of hepatocellular carcinoma.
Song KD; Choi D; Lee JH; Im GH; Yang J; Kim JH; Lee WJ
AJR Am J Roentgenol; 2014 Jun; 202(6):W559-66. PubMed ID: 24848850
[TBL] [Abstract][Full Text] [Related]
9. Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.
Kuczynski EA; Yin M; Bar-Zion A; Lee CR; Butz H; Man S; Daley F; Vermeulen PB; Yousef GM; Foster FS; Reynolds AR; Kerbel RS
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27059374
[TBL] [Abstract][Full Text] [Related]
10. In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media.
Cyran CC; Schwarz B; Paprottka PM; Sourbron S; von Einem JC; Dietrich O; Hinkel R; Clevert DA; Bruns CJ; Reiser MF; Nikolaou K; Wintersperger BJ
Cancer Imaging; 2013 Dec; 13(4):557-66. PubMed ID: 24380871
[TBL] [Abstract][Full Text] [Related]
11. Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.
Jeon TY; Kim CK; Kim JH; Im GH; Park BK; Lee JH
Br J Radiol; 2015 Sep; 88(1053):20150163. PubMed ID: 26133222
[TBL] [Abstract][Full Text] [Related]
12. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
[TBL] [Abstract][Full Text] [Related]
13. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma.
Nagel C; Armeanu-Ebinger S; Dewerth A; Warmann SW; Fuchs J
Exp Cell Res; 2015 Feb; 331(1):97-104. PubMed ID: 25447203
[TBL] [Abstract][Full Text] [Related]
15. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
17. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
Wang H; Zhang C; Chi H; Meng Z
Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
[TBL] [Abstract][Full Text] [Related]
18. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
19. Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis.
Haney CR; Fan X; Markiewicz E; Mustafi D; Karczmar GS; Stadler WM
Technol Cancer Res Treat; 2013 Feb; 12(1):71-8. PubMed ID: 22905809
[TBL] [Abstract][Full Text] [Related]
20. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]